ATG 107
Alternative Names: ATG-107Latest Information Update: 07 Nov 2024
At a glance
- Originator Antengene Corporation
- Class Bispecific antibodies; Immunoglobulin Fv fragments; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia